{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-24-000052","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.193029+00:00","generated_at":"2026-06-03T03:57:26.195477+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NeoGenomics Q1 revenue up 14% to $156M; Adjusted EBITDA turns positive at $3M","bullets":["Clinical Services revenue rose 17% to $135M; test volume up 5% YoY, revenue per test up 11% to $447.","Advanced Diagnostics revenue declined 3% to $22M; consolidated net loss narrowed 12% to $27M.","Adjusted EBITDA was $3M, a $10M improvement from -$7M in Q1 2023; cash and equivalents at $385M.","FY 2024 guidance reaffirmed: revenue $650M-$660M (10-12% growth), Adjusted EBITDA $21M-$24M.","CEO Chris Smith cited solid execution, NGS adoption growth, and consecutive revenue-per-test improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-24-000052","json":"https://secwatch.observer/filing/0001077183-24-000052.json","markdown":"https://secwatch.observer/filing/0001077183-24-000052.md","text":"https://secwatch.observer/filing/0001077183-24-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000052/0001077183-24-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000052/neo-20240430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:57:26.195477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"646b2e0043931b0c9ce7afc6740859425f705a8b","claim":"NEOGENOMICS INC reported the period ended March 31, 2024 results: revenue $156 million, net income Net loss of $27 million. Guidance reaffirmed.","evidence_excerpt":"NeoGenomics Reports First Quarter 2024 Results First Quarter Revenue Increased 14% to $156 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000052/0001077183-24-000052-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the period ended March 31, 2024"},{"label":"Revenue","value":"$156 million"},{"label":"Net income","value":"Net loss of $27 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}